Switzerland Archives

News and Trends 24 Mar 2016

Endeavouring to Establish Europe’s Largest MedTech Fund

The VC Endeavour Vision (Switzerland) has finally closed its Endeavour Medtech Growth (EMG) at €250M. This makes it one of the largest funds dedicated to MedTech innovation worldwide! Largely oversubscribed, the fund reached its hard cap and closed well above its €150M target, finally reaching €250M – the largest fund dedicated to medtech in Europe, and one of the largest pure […]

March 24, 2016 - 2 minutesmins - By Dani Bancroft

humabs influenza antibody infectious cellclone medimmune

News and Trends 24 Mar 2016

Novel Antibody for Influenza gets FDA Fast-Track Approval

Humabs (Switzerland) has gotten some serious recognition for its antibody platform, as its candidates for Influenza have received FDA fast-track designation. A biologic therapy for Influenza A has been granted Fast Track Designation by the FDA, a ‘programme to accelerate the treatment commercialisation. The therapy is based on an antibody (MEDI8852) that was initially developed by […]

March 24, 2016 - 3 minutesmins - By Denise Neves Gameiro

roche immuno oncology blueprint medicines boston

News and Trends 18 Mar 2016

Roche signs a €900M deal with an Immunotherapy Biotech in Boston

Roche (Switzerland) has picked 5 candidates from Blueprint Medicines (US) to complement its leading oncology pipeline. Roche is a leader in cancer therapies, but its position is threatened by intense competition, not to mention its stakes in the biosimilar war and some bad results from advanced trials. However, it seems that this Big Pharma still […]

March 18, 2016 - 3 minutesmins - By Denise Neves Gameiro

News and Trends 18 Mar 2016

Biotech of the Week: Addex Therapeutics, a Swiss Biotech on a Rollercoaster ride

This week we wave goodbye to the United Kingdom and all its glory and through the English channel, we head south to charming Switzerland. Geneva is our destination and it is where Addex Therapeutics, our Biotech of the Week, is based. City: Geneva (Switzerland) Founded: 2002 Employees: 5 Market Capitalization: €30M (3/2016) CEO: Tim Dyer Mission: Founded in […]

March 18, 2016 - 2 minutesmins - By Joachim Eeckhout

mission therapeutics sachs interview zurich labiotech biotech

News and Trends 16 Mar 2016

Interviewing the Biotech which raised the Biggest European Round in 2016 so far

Yesterday I flew to Switzerland for the day, to gage what was going on at the 9th Annual Sachs conference for European Biotech CEOs. Here I had the chance to Interview Cambridge UK’s Mission Therapeutics on investment and technology.. Panel discussions covered Partnering and Investment for various therapeutic platforms – in MedTech, Diagnostics and generally ‘Israel’ (and […]

March 16, 2016 - 1 minutemin - By Philip Hemme

leukemia mesothelioma myeloma sellas cancer immunoncology fda wt1

News and Trends 2 Mar 2016

Swiss Cancer Vaccine Gets 2 FDA Orphan Drug Designations

Sellas (Switzerland) is developing an immunotherapeutic cancer vaccine – which can be easier now that the FDA granted it Orphan Drug designations for two types of cancer (for the lung area and a type of leukemia). Sellas is a biopharma developing treatments for different cancers and diseases of the central nervous system (CNS). Its lead […]

March 2, 2016 - 3 minutesmins - By Denise Neves Gameiro

syngenta hong kong china monsanto biotech agribusiness

News and Trends 2 Mar 2016

Chinese Chemical Giant moves closer to buy Swiss Syngenta for €39.5Bn

Following Monsanto’s failed second attempt to merge with Syngenta, the Chinese seems to have better luck swaying this European chemical giant. Now ChemChina has its looking to secure a multi-billion loan facility for the acquisition. Syngenta is a well known agribusiness leader in agriculture and seeds production. This Swiss agro-tech was born in 2000 after the merger […]

March 2, 2016 - 2 minutesmins - By Joachim Eeckhout

News and Trends 26 Feb 2016

A New Super-Antibody against Ebola has been Isolated

Humabs BioMed (Switzerland), in collaboration with institutional partners has succeeded in isolating new antibodies against the Ebola virus and turned them into a potential therapy against it. Humabs discovers monoclonal antibodies by doing blood analysis of survivors to given infectious diseases. For example, if one wants the cure for the flu, it looks into people […]

February 26, 2016 - 3 minutesmins - By Denise Neves Gameiro

nestle health sciences pronutria investment amino acids food

News and Trends 25 Feb 2016

Boston Food Biotech Gets €38M from Nestlé

Pronutria (US) is a start-up out of Flagship Ventures developing nutritional therapies which has now gotten a huge equity investment from Nestlé Health Science (Switzerland). Pronutria is a cool Biotech start-up taking an innovative approach to treat diseases caused by amino acid imbalance, such as muscle loss, and neurological and liver complications. Besides being essential for protein synthesis, […]

February 25, 2016 - 3 minutesmins - By Denise Neves Gameiro

News and Trends 16 Feb 2016

This Swiss Bioinformatics Start-Up is Simplifying NGS and Data Driven Medicine for Hospitals

As one of the most successful medical bioinformatics start-ups in Europe, Sophia Genetics (Switzerland) has now forged a partnership with a US nucleic acid synthesis company to facilitate the transition to Data Driven Medicine. This Swiss start-up led the way in European medical informatics when their software earned accreditation to store patient genomic data – a true […]

February 16, 2016 - 2 minutesmins - By Denise Neves Gameiro

News and Trends 10 Feb 2016

“Actelion could be the First European-born Biopharma to make it to the Major League”

This is what the founder & CEO Jean-Paul Clozel of Actelion (Switzerland) said at the announcement of the 2015 financial results for the company. And it’s definitely true. Actelion is the only European born biopharma to have over 1K employees (in fact over 2,547 of them). This is already a big achievement but not their greatest… For example, in 2015, […]

February 10, 2016 - 2 minutesmins - By Philip Hemme

oxford biotech biomedica novartis car t cancer

News and Trends 1 Feb 2016

World CAR-T Leader Starts New Program with a UK Biotech

Pretty impressive CAR-T news coming from across the Channel… Oxford BioMedica just launched a second collaboration with Novartis, which has shown tremendous Phase II results – and the most advanced in CAR-T therapy in development so far (read our review on how CAR-T works and who else is working the field). This collaboration covers the […]

February 1, 2016 - 2 minutesmins - By Philip Hemme

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us